Presentation is loading. Please wait.

Presentation is loading. Please wait.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

Published byΚίμων Παυλόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with."— Presentation transcript:

1 Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with placebo (♦), irbesartan 150 mg (▪), and irbesartan 300 mg (▴) and 1 month after withdrawal of all antihypertensive treatment. Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with placebo (♦), irbesartan 150 mg (▪), and irbesartan 300 mg (▴) and 1 month after withdrawal of all antihypertensive treatment. Steen Andersen et al. Dia Care 2003;26: ©2003 by American Diabetes Association

Download ppt "Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with."

Similar presentations

Attenuation of the “White-Coat Effect” by Antihypertensive Treatment and Regression of Target Organ Damage by Gianfranco Parati, Luisa Ulian, Lorena Sampieri,

Attenuation of the “White-Coat Effect” by Antihypertensive Treatment and Regression of Target Organ Damage by Gianfranco Parati, Luisa Ulian, Lorena Sampieri,
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
Volume 67, Issue 6, Pages (June 2005)

Volume 67, Issue 6, Pages (June 2005)
Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Cumulative incidences of events, according to glucose-control strategy

Cumulative incidences of events, according to glucose-control strategy
Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.
Volume 60, Issue 1, Pages (July 2001)

Volume 60, Issue 1, Pages (July 2001)
Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.
Serum 25(OH)D levels stratified by the presence or absence of nephropathy. Serum 25(OH)D levels stratified by the presence or absence of nephropathy. The.

Serum 25(OH)D levels stratified by the presence or absence of nephropathy. Serum 25(OH)D levels stratified by the presence or absence of nephropathy. The.
(A) Urinary L-FABP (ULFABP) values in eight participants who had more than 5 µg/g creatinine (Cr) at the start of the study, at baseline and after treatment.

(A) Urinary L-FABP (ULFABP) values in eight participants who had more than 5 µg/g creatinine (Cr) at the start of the study, at baseline and after treatment.
The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.
Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.
Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.
A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.
Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and exocytosis. Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and.

Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and exocytosis. Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and.
Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),
Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.

Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.

Similar presentations

Ads by Google